Targeting the IL-17 Pathway in Inflammatory Disorders

Author:   Cong-Qiu Chu
Publisher:   Springer International Publishing AG
Edition:   1st ed. 2017
ISBN:  

9783319280394


Pages:   102
Publication Date:   28 December 2016
Format:   Paperback
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Our Price $145.17 Quantity:  
Add to Cart

Share |

Targeting the IL-17 Pathway in Inflammatory Disorders


Add your own review!

Overview

Full Product Details

Author:   Cong-Qiu Chu
Publisher:   Springer International Publishing AG
Imprint:   Adis
Edition:   1st ed. 2017
Dimensions:   Width: 12.70cm , Height: 0.70cm , Length: 20.30cm
Weight:   1.529kg
ISBN:  

9783319280394


ISBN 10:   3319280392
Pages:   102
Publication Date:   28 December 2016
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Reviews

Author Information

Cong-Qiu Chu, MD, PhD is associate professor of medicine at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon. Dr Chu obtained his MD from Normal Bethune University of Medical Sciences, Changchun, China and PhD from the Kennedy Institute of Rheumatology, University of London, London, UK; completed his internal medicine residency at Peking Union Medical College Hospital, Beijing and Wayne State University Detroit Medical Center, Detroit, Michigan and rheumatology fellowship at University of Washington, Seattle. Dr Chu has a career long interest in the pathogenesis of rheumatoid arthritis (RA). His seminal observation that tumor necrosis factor (TNF) is over-expressed in RA joint tissue helped the development of TNF inhibitors for therapy of RA. His contribution was recognized by European League Against Rheumatism Young Investigator Award in 1991. Dr Chu is one of the investigators who first demonstrated that T helper type 1 (Th1) cells are not the cell types mediating autoimmune inflammatory diseases, which were later uncovered to be mediated by Th17 cells. Dr Chu’s current research includes developing novel therapeutic strategies using RNA interference technology for precise targeting Th17 cells for inflammatory diseases and developing optimal management strategies for early RA.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List